Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB4594 in Advanced Malignancies
NCT06380816Phase 2Recruiting
- Sponsor
- Cancer Research UK
- Start
- Jul 2024
- Primary completion
- Nov 2029
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of UCB4594 in solid tumor (advanced stage), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 8 more (2 arms), sponsored by Cancer Research UK. Primary endpoints: Recommended Phase 2 Dose at 21 days and Adverse Events at 12 months. Started Jul 2024; status: recruiting.
02
Drugs
UCB4594
03
Conditions
solid tumor (advanced stage)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06380816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380816.